Immune_related_adverse_events_GI_toxicity_colitis v.0
Immune-Related Adverse Events for GI Toxicity - Colitis grades severity of colitis secondary to immune checkpoint inhibitor therapy.
To grade severity of colitis secondary to immune checkpoint inhibitor therapy.
Colitis grade: CTCAE for diarrhea: G1 Increase of <4 stools per day over baseline; mild increase in ostomy output compared with baseline G2 Increase of 4-6 stools per day over baseline; moderate increase in ostomy output compared with baseline G3 Increase of ≥7 stools per day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared with baseline; limiting self-care/activities of daily living G4 Life-threatening consequences; urgent intervention indicated
1. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768.
EVALUATION.immune_related_adverse_events_gi_toxicity_colitis.v0
